Clinical trials: Autoimmune Encephalitis
Autoimmune Encephalitis
Neuro-ophthalmology and Autoimmune Encephalitis (NODE)
Autoimmune encephalitis represents a group of rare and heterogeneous neurological disorders. Pathophysiological mechanisms in these diseases are still unknown. Recently, oculomotor and neurovisual disorders have been described.
- Trial name
- NODE (NCT03872284)
- Testing
- oculomotor movement recordings, neurovisual assessment
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Hospices Civils de Lyon
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Trial name
- NCT07526493
- Testing
- Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Tongji Hospital
Psychosis, Autoimmune Encephalitis
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
A randomised phase II double-blinded placebo-controlled trial designed to explore the utility of immunotherapy for patients with acute psychosis associated with anti-neuronal membranes (NMDA-receptor or Voltage Gated Potassium…
- Trial name
- SINAPPS2 (NCT03194815)
- Testing
- Intravenous immunoglobulin, Rituximab
- Where
- 10 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- University of Cambridge
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Autoimmune encephalitis is an autoimmune disease of the central nervous system that targets neuronal autoantigens. Anti-neuronal autoantibodies are produced in patients, with anti-NMDAR antibody being the most common.Anti-NMDAR…
- Trial name
- RADIA (NCT06867991)
- Testing
- Ofatumumab combined with daratumumab, Ofatumumab, Repeated intravenous immunoglobulin/plasma exchange therapy
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- The First People's Hospital of Changzhou
Chronic Focal Encephalitis, Rasmussen's Encephalitis
A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis
The purpose of this study is to assess the safety, tolerability and effectiveness of rituximab in the treatment of chronic focal encephalitis.
- Trial name
- NCT00259805
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- California Pacific Medical Center Research Institute
Autoimmune Encephalitis
Efficacy of Ocrelizumab in Autoimmune Encephalitis
This pilot study is a randomized, double-blind, placebo controlled study of the efficacy of ocrelizumab in autoimmune encephalitis. Subjects with new diagnosis of autoimmune encephalitis will be invited to enroll in this study.
- Trial name
- NCT03835728
- Testing
- Ocrelizumab, Saline
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Texas Southwestern Medical Center
Autoimmune Encephalitis
Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis.
First described in 2010, GABA-B-receptor antibodies-associated encephalitis is a disease with a severe vital and functional prognosis.
- Trial name
- SALTEA GABAbr (NCT05741619)
- Testing
- Long-term outcome
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Hospices Civils de Lyon
Paraneoplastic Neurological Syndrome, Autoimmune Encephalitis
Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
Autoimmune encephalitis (AE) is a rare neurological disorder mediated by autoimmune antibody response against neuronal cell surface and intraneuronal proteins associated with specific brain areas, resulting in severe inflammation…
- Trial name
- MIDAS (NCT06432803)
- Testing
- PET-Scan analysis
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Hospices Civils de Lyon
Encephalitis
IL-2 in Refractory Autoimmune Encephalitis
The purpose of this study is to determine whether low-dose IL-2 is effective in refractory autoimmune encephalitis.
- Trial name
- NCT02714959
- Testing
- Proleukin
- Volunteers
- 10 people
- Sponsor
- Seoul National University Hospital
Anti-IgLON5 Disease
Clinical Characterization and Outcome of Anti-IgLON5 Disease
Anti-IgLON5 disease is a neurological disorder associated with antibodies to IgLON5, a neuronal cell adhesion protein of unknown function.
- Trial name
- ICP-IGLON5 (NCT06131346)
- Testing
- Evaluation of clinical and paraclinical data.
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon
Limbic Encephalitis With LGI1 Antibodies
Antibody-mediated LGI1 Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Chronic Phase of the Disease
The encephalitis mediated by antibodies against Leucine-rich, glioma inactivated 1 protein (anti-LGI1 encephalitis) predominantly affects men (M:F, 6:4) and mostly older than 60 years.
- Trial name
- NCT06515106
- Testing
- Remote cognitive rehabilitation program
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Encephalitis Autoimmune
Efgartigimod in Anti-NMDA Receptor Encephalitis.
This study is a multicenter, open-label, single-arm exploratory trial designed to enroll 20 eligible patients with anti-NMDAR encephalitis.
- Trial name
- ANSWER (NCT07822776)
- Testing
- Efgartigimod Alfa
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tongren Hospital
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
- Trial name
- Cielo (NCT05503264)
- Testing
- Satralizumab
- Where
- 56 sites in United States, Argentina and 13 more
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
CASPR2-Antibody, Encephalitis Autoimmune
CASPR2 Encephalitis Initial Symptoms
Auto-immune encephalitides involve auto-antibodies targeting the central nervous system, and particularly the synapse and its structure, such as protein CASPR2.
- Conditions
- CASPR2-Antibody, Encephalitis Autoimmune, Paraneoplastic Syndromes
- Trial name
- iniCASPR2 (NCT04653571)
- Testing
- CASPR2 encephalitis
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Hospices Civils de Lyon
Rheumatic Diseases, Lupus Erythematosus, Systemic
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Background: Rheumatic diseases can affect the joints, ligaments, tendons, bones, muscles, and skin. They can also cause inflammation, damage body tissues, and change nerve signals in the brain.
- Conditions
- Rheumatic Diseases, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Arthritis
- Trial name
- NCT07829497
- Testing
- Bedside quantitative sensory testing
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Multiple Sclerosis, NMO Spectrum Disorder
Tongji NADs Cohort
Neurological Autoimmune Diseases (NADs) are disorders caused by abnormal immune system attacks on neural tissues, affecting multiple systems including the central nervous system, peripheral nervous system, and neuromuscular…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Trial name
- NCT07333196
- Testing
- No active interventions
- Where
- China
- Volunteers
- 1,550 people
- Sponsor
- Tongji Hospital
Autoimmune Encephalitis
Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis
To compare the efficacy and safety of NPB-01 in patients with autoimmune encephalitis refractory to steroid pulse therapy using steroid pulse therapy as a control.
- Trial name
- NCT05177939
- Testing
- NPB-01, NPB-01-ME
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Autoimmune Encephalitis, Early-stage Panencephalitis
Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes
This is a prospective, non-randomized, observational registry study evaluating the clinical outcomes of patients with autoimmune or post-infectious neuroinflammatory syndromes receiving stem cell-derived biologics (including…
- Conditions
- Autoimmune Encephalitis, Early-stage Panencephalitis, Neuroinflammatory Demyelination
- Trial name
- NCT07145502
- Testing
- Allogeneic MSC infusions (IV)
- Where
- Poland
- Volunteers
- 76 people
- Sponsor
- Biocells Medical
Autoimmune Encephalitis, Paraneoplastic Neurological Syndrome
HLA Analysis in Autoimmune Encephalitis and Related Disorders: Part II
Autoimmune encephalitis (AE) are characterized by subacute onset of memory deficits, altered mental status or psychiatric symptoms, frequently associated with seizures, inflammatory cerebrospinal fluid and in cases with prominent…
- Trial name
- ICARE-II (NCT04823728)
- Testing
- Autoimmune encephalitis and paraneoplastic neurological syndromes
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Hospices Civils de Lyon
Multiple Sclerosis, NMO Spectrum Disorder
National, Multicentric Registry Study on Neuroimmunological Diseases in China
The aim of this study is to establish a real-world clinical neuroimmune disease research cohort, to follow up and observe the prognosis of patients with different subtypes and subgroups, and to provide support for the treatment…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Myasthenia Gravis
- Trial name
- NIDBase (NCT06443333)
- Testing
- Data collection and follow-up observation, Data collection
- Where
- China
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing